Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-, also known as 2,2-diMethyl-3-butyn-1-yl benzene, is a chemical compound with the molecular formula C13H16. It is a colorless liquid characterized by a fruity odor. Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]is utilized in various industrial applications due to its unique properties, although it requires careful handling to prevent potential health hazards.

1092536-54-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1092536-54-3 Structure
  • Basic information

    1. Product Name: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-
    2. Synonyms: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-;4-Benzyloxy-3,3-diMethylbut-1-yne;(((2,2-diMethylbut-3-yn-1-yl)oxy)Methyl)benzene;EOS-60787
    3. CAS NO:1092536-54-3
    4. Molecular Formula: C13H16O
    5. Molecular Weight: 188.26554
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1092536-54-3.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 255.6±23.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 0.965±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-(CAS DataBase Reference)
    10. NIST Chemistry Reference: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-(1092536-54-3)
    11. EPA Substance Registry System: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-(1092536-54-3)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1092536-54-3(Hazardous Substances Data)

1092536-54-3 Usage

Uses

Used in Chemical Production:
Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]is used as a solvent for various chemical processes, facilitating reactions and improving the efficiency of production.
Used in Pharmaceutical Synthesis:
Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]plays a crucial role in the synthesis of pharmaceuticals, contributing to the development of new medications and therapies.
Used in Adhesives, Sealants, and Coatings Manufacturing:
Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]is used as a component in the production of adhesives, sealants, and coatings, enhancing their performance and durability.
Used in the Synthesis of Other Chemicals:
It serves as a precursor in the synthesis of other chemicals, expanding its utility across different industries.

Check Digit Verification of cas no

The CAS Registry Mumber 1092536-54-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,5,3 and 6 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1092536-54:
(9*1)+(8*0)+(7*9)+(6*2)+(5*5)+(4*3)+(3*6)+(2*5)+(1*4)=153
153 % 10 = 3
So 1092536-54-3 is a valid CAS Registry Number.

1092536-54-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name {[(2,2-Dimethyl-3-butyn-1-yl)oxy]methyl}benzene

1.2 Other means of identification

Product number -
Other names 1-O-benzyl-1,5,6-hexanetriol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1092536-54-3 SDS

1092536-54-3Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF TEZACAFTOR INTERMEDIATE

-

Page/Page column 14, (2021/03/05)

The present invention relates to an improved process for the preparation of tezacaftor intermediate compound of formula II. More particularly, the present invention relates to an improved, commercially viable process for the preparation of tezacaftor inte

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

-

, (2021/04/21)

The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES

-

Paragraph 0468; 0471, (2017/05/14)

The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

-

, (2016/08/03)

The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

-

, (2015/09/22)

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

PHARMACEUTICAL COMPOSITIONS OF (R)-1-(2,2-DIFLURORBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF

-

, (2014/02/15)

A pharmaceutical composition comprising Compound 1, (R)- 1 -(2,2- difluorobenzo[d] [ 1,3]dioxol-5-yl)-N-( 1 -(2,3-dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2- methylpropan-2-yl)- l H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from : a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide

-

, (2013/06/26)

The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.

PHARMACEUTICL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS

-

, (2014/01/08)

The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5- hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxaraide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound ? in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxoI- 5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3- dihydroxypropyl)~6~fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)- 1H-indol-5- yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to solid forms and formulations of Compound 2 or Compound 3 in combination with Compound 1, and pharmaceutical compositions thereof, for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

-

, (2013/05/21)

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Total synthesis of debromoflustramines B and e based on the intramolecular carbamoylketene-alkene [2 + 2] cycloaddition

Ozawa, Tsukasa,Kanematsu, Makoto,Yokoe, Hiromasa,Yoshida, Masahiro,Shishido, Kozo

supporting information, p. 9240 - 9249,10 (2012/12/12)

Total synthesis of debromoflustramines B and E has been accomplished by using a platinum-catalyzed addition reaction of o-aminophenylboronic acid with the allene and an intramolecular carbamoylketene-alkene [2 + 2] cycloaddition for the construction of the basic carbon framework of the target alkaloids as the key steps.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1092536-54-3